Skip to content
value.today

NeurogesX Inc

Formerly Advanced Analgesics, Inc.

Total raised
$25 M
3 rounds on record
Latest round
$3 M
Feb 2012
First round on record
Jul 2011
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of NeurogesX Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2012$3 MNo. 3$2 to $10 million

NeurogesX Inc: Raise no. 3, Feb 2012

Investors in this round

6 investors had bought by the notice of Feb 8, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Michael F. Markels · Executive Officer
  • Ronald A. Martell · Executive Officer, Director
  • Stephen F. Ghiglieri · Executive Officer
  • Stephen F. Peroutka · Executive Officer
  • Anthony F. DiTonno · Director
  • Bradford F. Goodwin · Director
  • Gary F. Lyons · Director
  • Jean-Jacques F. Bienaime · Director
  • John F. Orwin · Director
  • Neil F. Kurtz · Director
  • Robert F. Nelsen · Director
  • Steven F. Nelson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Funds to be used for working capital.”

Signed by Stephen Ghiglieri, CFO, COO & Executive Vice President. Source: SEC Form D, newest notice filed Feb 8, 2012. Read the notice at the SEC.

equitySEC
Aug 2011$1 MNo. 2Under $2 million

NeurogesX Inc: Raise no. 2, Aug 2011

Investors in this round

1 investor had bought by the notice of Aug 17, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Anthony A. DiTonno · Executive Officer, Director
  • Jeffrey K. Tobias · Executive Officer
  • Michael E. Markels · Executive Officer
  • Stephen F. Ghiglieri · Executive Officer
  • Bradford S. Goodwin · Director
  • Gary A. Lyons · Director
  • Jean-Jacques A. Bienaime · Director
  • John A. Orwin · Director
  • Neil M. Kurtz · Director
  • Robert M. Nelsen · Director
  • Steven H. Nelson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Funds to be used for working capital.”

Signed by Michael J. O'Donnell, Secretary. Source: SEC Form D, newest notice filed Aug 17, 2011. Read the notice at the SEC.

optionsSEC
Jul 2011$20 MNo. 1$10 to $50 million

NeurogesX Inc: Raise no. 1, Jul 2011

Investors in this round

29 investors had bought by the notice of Aug 3, 2011: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,010,461
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Anthony A. DiTonno · Executive Officer, Director
  • Jeffrey K. Tobias · Executive Officer
  • Michael E. Markels · Executive Officer
  • Stephen F. Ghiglieri · Executive Officer
  • Bradford S. Goodwin · Director
  • Gary A. Lyons · Director
  • Jean-Jacques A. Bienaime · Director
  • John A. Orwin · Director
  • Neil M. Kurtz · Director
  • Robert T. Nelsen · Director
  • Steven H. Nelson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Swann LLC (CRD 39011) · Boston, MassachusettsSold in CA, IL, MA, NY, OK, UT, WA, and outside the US

Remarks in the notice

  • On the use of proceeds: “Funds to be used for working capital.”

Signed by Stephen Ghiglieri, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 3, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NeurogesX Inc chose not to state its revenue in its newest notice of a funding round (Feb 2012).

    SEC Form D · Feb 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2012

That is all the official record says: NeurogesX Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of NeurogesX Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 29 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NeurogesX Inc
NameRoleNamed in
Michael F. MarkelsExecutive officerFeb 2012
Ronald A. MartellExecutive officerFeb 2012
Stephen F. GhiglieriExecutive officerFeb 2012
Stephen F. PeroutkaExecutive officerFeb 2012
Anthony A. DiTonnoExecutive officerAug 2011
Jeffrey K. TobiasExecutive officerAug 2011
Michael E. MarkelsExecutive officerAug 2011
Anthony F. DiTonnoDirectorFeb 2012
Bradford F. GoodwinDirectorFeb 2012
Gary F. LyonsDirectorFeb 2012
Jean-Jacques F. BienaimeDirectorFeb 2012
John F. OrwinDirectorFeb 2012
Neil F. KurtzDirectorFeb 2012
Robert F. NelsenDirectorFeb 2012
Ronald A. MartellDirectorFeb 2012
Steven F. NelsonDirectorFeb 2012
Anthony A. DiTonnoDirectorAug 2011
Bradford S. GoodwinDirectorAug 2011
Gary A. LyonsDirectorAug 2011
Jean-Jacques A. BienaimeDirectorAug 2011
John A. OrwinDirectorAug 2011
Neil M. KurtzDirectorAug 2011
Robert M. NelsenDirectorAug 2011
Steven H. NelsonDirectorAug 2011
Robert T. NelsenDirectorAug 2011